scPharmaceuticals (SCPH) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Patient and physician adoption trends

• Repeat patient prescriptions are increasing, indicating strong product adoption and satisfaction.

• Repeat usage by both patients and doctors signals positive field performance.

• Complaint and adverse event rates remain under 1%, reflecting high effectiveness and safety.

Sales force expansion and operational strategy

• Initial launch began with 40 reps, expanded to 68 last year, and is reaching 90 this quarter.

• Further expansion to 125-130 reps is planned with the kidney indication launch in March.

• Sales force growth is paced to match market creation and product learning.

Prescription trends and product mix

• Average units per prescription have risen from an expected 4 to closer to 6 due to patient mix.

• Class IV heart failure approval is driving higher script counts, with some patients prescribed up to 12 units per month.

• Prophylactic use in severe patients and expanded post-discharge use are key growth drivers.